It is made available under a CC-BY 4.0 International license .

Accelerated absorption of regular insulin administered via a vascularizing permeable microchamber implanted subcutaneously in diabetic *Rattus*

norvegicus

- 1 Short title: Rapid insulin absorption via a subcutaneously implanted microchamber in *R. norvegicus*
- 2 Leah V. Steyn¹, Delaney Drew¹, Demetri Vlachos¹, Barry Huey¹, Katie Cocchi¹, Nicholas D.
- 3 Price¹, Robert Johnson², Charles W. Putnam¹, and Klearchos K. Papas^{1,2*}
- 4 ¹Institute for Cellular Transplantation, Department of Surgery, University of Arizona College of
- 5 Medicine-Tucson, University of Arizona, Tucson, AZ, USA
- ⁶ ²Procyon Technologies, LLC., Medical Research Building (Room 121), University of Arizona,
- 7 Tucson, AZ, USA
- 8 *Corresponding author
- 9 Email: <u>kkpapas@surgery.arizona.edu</u> (KPP)
- 10 Keywords: insulin, diabetes, microchamber, subcutaneous, rat, absorption, vascularizing,
- 11 pharmacokinetics

It is made available under a CC-BY 4.0 International license .

12 Abstract

13	In Type 1 diabetes patients, even ultra-rapid acting insulins injected subcutaneously reach
14	peak concentrations in 45 minutes or longer. The lag time between dosing and peak concentration, as
15	well as intra- and inter-subject variability, render prandial glucose control and dose consistency
16	difficult. We postulated that insulin absorption from subcutaneously implantable vascularizing
17	microchambers would be significantly faster than conventional subcutaneous injection. Male athymic
18	nude R. norvegicus rendered diabetic with streptozotocin were implanted with vascularizing
19	microchambers (single chamber; 1.5 cm2 surface area per side; nominal volume, 22.5 μ L). Plasma
20	insulin was assayed after a single dose (1.5 U/kg) of diluted insulin human (Humulin®R U-100),
21	injected subcutaneously or via microchamber. Microchambers were also implanted in additional
22	animals and retrieved at intervals for histologic assessment of vascularity. Following conventional
23	subcutaneous injection, the mean peak insulin concentration was 22.7 (SD 14.2) minutes. By
24	contrast, when identical doses of insulin were injected via subcutaneous microchamber 28 days after
25	implantation, the mean peak insulin time was shortened to 7.50 (SD 4.52) minutes. Peak insulin
26	concentrations were similar by either route; however, inter-subject variability was reduced when
27	insulin was administered via microchamber. Histologic examination of tissue surrounding
28	microchambers showed mature vascularization on days 21 and 40 post-implantation. Implantable
29	vascularizing microchambers of similar design may prove clinically useful for insulin dosing, either
30	intermittently by needle, or continuously by pump including in "closed loop" systems, such as the
31	artificial pancreas.

It is made available under a CC-BY 4.0 International license .

33 Introduction

34	In response to perturbations of plasma glucose concentration and other physiologic cues, the
35	normal endocrine pancreas modulates its release of insulin (and other hormones); insulin, entering
36	the portal venous circulation in approximately five second pulses and longer oscillations, rapidly and
37	precisely maintains glucose homeostasis [1]. In Type 1 diabetes mellitus (T1DM), the endocrine
38	pancreas fails to produce insulin in sufficient quantities, if at all [2]. Although pharmacologic insulins
39	are a life-saving therapy, they fail to mimic the rapidity and precision of glucose modulation
40	conferred by the normal pancreas [3]. Consequently, despite insulin therapy, diabetic patients remain
41	vulnerable to a range of costly, long-term, disabling complications.
42	Pharmacologic insulins are most often injected into the subcutaneous (SC) tissue of the
43	abdominal wall or extremities; however, because of the relative avascularity of SC tissue [4], the
44	dispensed insulin - depending upon its formulation - may require an hour or longer to attain its peak
45	concentration in the blood [4]. This delay in absorption renders insulin therapy an exercise in
46	predictive dosing, especially when anticipating the substantial swings in blood glucose concentration
47	encountered during and following meals [5]. The lag time between SC dosing and achieving an
48	effective insulin concentration in the blood also blunts the precision otherwise afforded by
49	continuous glucose monitoring (CGM) devices, sophisticated dosing decision algorithms, precision
50	insulin pumps, open- or closed-loop systems, and the "artificial pancreas" [4, 6].
51	Efforts to accelerate absorption of insulin have pursued two general approaches: novel
52	formulations of pharmacologic insulins and altered routes of administration. One or more amino acid
53	changes of the insulin molecule itself [7-12] and/or the addition of chemicals [13] reduce the
54	tendency of native insulin to form multimeric complexes which first must dissociate into monomers

It is made available under a CC-BY 4.0 International license .

55	or dimers in order to be absorbed [14]. These modifications of pharmacologic insulin have yielded
56	only incremental increases in the rate of absorption (reviewed in [4, 15]). Consequently, ultra-rapid
57	insulins have not achieved wide-spread patient acceptance [4], in part because of increased drug costs
58	[15] and a greater frequency of injection site reactions [16].
59	The second approach – alternative routes of administration affording more rapid uptake of
60	insulin - have included intradermal microinjection [17] or "jet spray" [18, 19], intraperitoneal
61	instillation [20, 21], or the inhalation of specially formulated insulins [22, 23]. None of these
62	strategies has gained widespread clinical acceptance, in part because of unpredictable dosing,
63	increased complication rates, and patient hesitancy [24, 25].
64	Although the lag times between SC injection and peak time (T _{max}) have been somewhat
65	foreshortened by the development of "ultra-rapid acting insulins" [Faster aspart (Fiasp), 63 min,
66	URLj (Lyumjev), 57 min [15]], the subcutaneous route is beleaguered by a second confounding
67	problem: intra-patient variability of absorption of the specified dose [26-28] resulting in
68	unanticipated blood glucose effects. This variance between anticipated and actual effect upon blood
69	glucose concentration contributes to the incidence of both diabetic ketoacidosis (DKA) and
70	importantly, hypoglycemic episodes [6], especially in those individuals who are constitutively
71	"hypoglycemia unaware" [29, 30].
72	Unpredictable discrepancies between the intended and evinced biochemical effects of a
73	particular SC dose are multifactorial. The vascularity of the subcutaneous space is not homogenous
74	even within individuals [22, 31-35] and the SC composition is further altered by repeated injections
75	[36, 37]. In a 2018 review [38], the multitude of factors affecting absorption of SC insulin are

76 discussed in detail; they include, among many others: variations in the depth of needle penetration,

77 including inadvertent intramuscular injection; dislodged catheters or mechanical issues associated

with insulin pump infusion sets [39]; and seepage of drug from the injection site. It stands to reason
that intra-patient variability compounds inter-patient dosage algorithms; predictions and comparisons
are therefore fraught, requiring complex modeling [40, 41].

81 To address the challenges posed by lagging absorption of even ultra-fast insulins and the 82 inconsistency of intrasubject dosing, we evaluated in a diabetic *R. norvegicus* model, subcutaneously 83 implantable vascularizing microchambers, IVMs (Fig 1A). These microchambers - of various 84 footprints and capacities – are engineered of polytetrafluoroethylene membranes (PTFE) and have a 85 surface configuration which promotes angiogenic ingrowth; an inner membrane simultaneously 86 blocks host cells from entering and occupying the microchamber [42]. We report here that the IVM, 87 implanted in the SC space, accelerates the absorption of inexpensive regular human insulin, 88 achieving pharmacokinetic profiles potentially superior to ultra-rapid acting insulins. Importantly, 89 our data also suggest that the IVM improves consistency of insulin delivery, thereby potentially 90 avoiding hazardous deviations in blood glucose concentration. 91 92 Fig 1. The Procyon implantable vascularizing microchamber (IVM) and an illustrative clinical

93 application.

94 (A) The vascularizing, microchamber (depicted before implantation), fabricated of PTFE, has a

95 surface area per side of 1.5 cm² and a nominal volume of 22.5μ L. (B) One potential clinical

96 application of the IVM is to couple it with an insulin pump. The *infusion set* connects the *insulin*

- 97 *pump* to the SC implanted *microchamber*; the IVM's *connection tubing* is fitted with a *heal in place*
- 98 *cuff* fabricated from material that promotes vascularization. (C) A schematic of the vascularized
- 99 microchamber, depicting the ingrowth of blood vessels to its surface and the flow of insulin from

It is made available under a CC-BY 4.0 International license .

100 within the microchamber, through the permeable membranes, and into the richly vascularized SC

101 space surrounding the IVM.

102

103 Materials and methods

104 **Experimental animals**

105 Male athymic nude <i>R. norvegicus</i> between 9 - 12 weeks of age and weighing	250 - 350 g were
---	------------------

106 purchased from Envigo (Livermore, CA, USA). Animals were housed for a seven-day

107 acclimatization period before initiating any experimental procedures. All experiments were

108 performed with the approval of, and in accordance with guidelines established by, the Institutional

109 Animal Care and Use Committee (IACUC) at The University of Arizona.

110 Induction of diabetes

111 To avoid endogenous insulin in subject rats from cross-reacting in the human insulin assays, 112 animals were rendered diabetic by a single intraperitoneal injection, 60 mg/kg, of streptozotocin 113 (Sigma-Aldrich, St. Louis, MO, USA). Blood glucose concentrations were monitored daily using a 114 Freestyle Lite Glucose Monitoring System (Abbott Diabetes Care Inc., Alameda, CA, USA). Rats 115 were considered diabetic when blood glucose concentrations greater than 200 mg/dL were recorded 116 on three consecutive days. Rats verified as diabetic were maintained with exogenous long-acting 117 insulin (Lantus, Sanofi-Aventis, Bridgewater, NJ, USA) throughout the study; maintenance insulin 118 treatment also serves to forestall insulin resistance [43]. Maintenance insulin therapy was suspended 119 for 24 hours prior to each insulin kinetics study.

It is made available under a CC-BY 4.0 International license .

120 Implantation of vascularizing microchambers (IVMs)

121	Two days after the initial insulin-kinetics assay two empty, 1.5cm ² per side, single-chamber
122	(having a nominal internal volume of 22.5 μ L), implantable vascularizing microchambers, IVMs
123	(Procyon Technologies LLC, Tucson, AZ, USA) (Fig 1A) were implanted subcutaneously on the
124	dorsal aspect of each rat.

125 Insulin kinetics assays

126 Subcutaneous injection of human insulin

The initial insulin kinetics assays were performed 7 days after STZ induction of diabetes.
Nonfasted rats received a single subcutaneous injection of insulin human, 1.5 U/kg (Humulin R;
Lilly, Indianapolis, IN, USA). Each dose of insulin was diluted in 0.5 mL of sterile saline (0.9%)
solution, then injected subcutaneously using a glass Hamilton syringe fitted with a 20-gauge sharp
needle.

132 Blood sample collection

133 Blood samples (150 μ L) were collected from the tail vein before injection (time = 0), and at 5-,

134 15-, 30-, 60-, 90-, and 120-minutes following injection. Blood samples for insulin assays were stored

- 135 on ice in 1.5 mL centrifuge tubes with EDTA until separation of plasma by centrifugation at 13,300 x
- 136 g for 15 minutes at 4° C. Plasma samples were stored at -20° C.

137 Administration of human insulin via subcutaneously implanted IVMs

It is made available under a CC-BY 4.0 International license .

On day 28 post-implantation, each rat received a single dose of insulin human, Humulin R, 1.5 U/kg (Lilly, Indianapolis, IN, USA), diluted as described above. The insulin was then instilled into one of the two IVMs via its port. Blood samples for plasma insulin were collected and processed as described above.

142 Analysis of rat plasma samples for human insulin concentration

143 Plasma samples collected from each insulin kinetics assay were analyzed for human insulin

144 concentration using a commercial human insulin ELISA kit (Alpco, Salem, NH, USA). Samples

145 were run in duplicate. The ELISA kit has a detection range of 3.0-200 µIU/mL and a sensitivity of

146 0.399 μ IU/mL. The measured insulin concentrations were converted from IU/mL to μ g/mL

147 according to the manufacturer's recommended conversion ratios of 1 IU of human insulin = 6nmol =

148 34.8 μg of insulin.

149 **IVM retrieval and histopathology**

At the conclusion of the study (day 40), rats were euthanized, and the IVMs were retrieved for histology. Additional specimens were obtained 7 and 21 days after implantation from rats in a cohort not included in the insulin analyses reported herein. After removal, each IVM including its adherent tissue was placed in 10% neutral buffered formalin for fixation, then processed for paraffin embedding. Paraffin blocks were sectioned and 5μ M slices were collected throughout the microchamber. Sections were stained with hematoxylin and eosin and imaged with a Keyence BZ-X710 microscope (Keyence Co, Osaka, Japan).

157 Statistical analysis

It is made available under a CC-BY 4.0 International license .

158 Insulin kinetic curves

The concentrations of human insulin in each rat were normalized to zero by simple subtraction of the variance at t = 0 from all values for that animal. The insulin kinetic curves were created by calculating the mean values and standard deviations at each time point. In several instances, complete plasma insulin concentration data were not obtained for a given rat in a particular assay; if more than three of the seven data points were unavailable, the subject was excluded from analysis. Data from one animal in the subcutaneous injection (control) group was excluded from analysis on that basis.

165 **Peak insulin times and concentrations**

166 The mean peak times (T_{max}) and concentrations of the insulin kinetic assays were obtained as 167 follows: for each subject the greatest plasma insulin concentration was identified, and both the time point (e.g., 10 min) and the insulin concentration at that time point were tabulated. The mean and SD 168 169 for each category were then calculated. The two assays, subcutaneous injection at day -2, and IVM 170 administration on day 28, were compared by the unpaired, two-tailed, t-test. The full kinetic curves 171 were compared with the nonparametric Friedman's test [44]. Statistical tests were conducted with 172 GraphPad Prism version 9.4.1 for Windows (GraphPad Software, San Diego, California USA, 173 www.graphpad.com).

174 **Results**

175 Insulin-kinetics study after subcutaneous (SC) injection in diabetic rats

Five days after successful induction of STZ diabetes, rats were injected subcutaneously with diluted human insulin (Humulin R), followed by blood sampling for plasma insulin concentration over a two-hour period. Consonant with the extensive literature documenting inter-subject variability

It is made available under a CC-BY 4.0 International license .

179	of insulin absorption after SC injection, the individual insulin curves were quite variable in timing
180	and concentration between animals (Fig 2A), with no clear peak by visual inspection (Fig 2C). The
181	mean peak of plasma insulin – T_{max} – was calculated as 22.7 (n=11, SD 14.2, 95% CI 13.18 – 32.27)
182	min post-injection and the peak concentrations averaged 12.3 (SD 3.16) ng/ml (Table 1). In the
183	experiments described above, the Humulin R stock suspension was diluted in 500 uL sterile saline,
184	approximately a 100-fold dilution. Because the rate of insulin absorption directly correlates with the
185	concentration of mono- and dimers, dilution of the stock solution might seem to favor dissociation of
186	multimeric insulin [9, 14]. In another experiment we compared two concentrations – diluted versus
187	stock – of Humulin R insulin after SC injection. The plasma insulin curves did not vary significantly
188	between the two concentrations (unpublished data), confirming that dilution of Humulin R did not
189	per se affect its rate of absorption.

190

191 Fig 2. Plasma insulin kinetics after either SC or IVM injection of regular insulin.

Plasma concentrations of human insulin were collected over 120 minutes following either subcutaneous injection (A,C) or instillation into subcutaneous IVMs 28 days after implantation (B,D) of regular insulin human (Humulin R) in identical doses. Shown in A and B are the data for the individual subjects in each group of rats; in C and D are the insulin kinetic curves generated by plotting means and standard deviations (SD). N=11 rats in the SC injection group (one rat was excluded from the analysis because of incomplete plasma insulin concentration data); N=12 rats in the IVM group.

200 Table 1. Mean peak times and concentrations of plasma insulin after subcutaneous or IVM

201 injection in diabetic rats of insulin human (1.5 U/kg body weight).

	Subcutaneous injection	IVM injection on day 28
Number of subjects (n)	11	12
Body weight (g)	302.1 (SD 25.1)	364.9 (SD 29.6)
T _{max} (min)	22.7 (SD 14.2)	7.50 (SD 4.52) **
95% CI of T _{max} (min)	13.18 - 32.27	4.626 - 10.39
Insulin concentration (ng/ml)	12.3 (SD 3.16)	11.7 (SD 4.97) NS

Given are means, standard deviations (SD), and 95% Confidence Intervals (CI). Although the peak concentrations are not significantly different (NS), the interval to peak concentration (T_{max}) was significantly shorter (** p=0.0020, by the unpaired, two-tailed t test) when insulin was delivered via microchamber.

206

207 Insulin kinetics after administration via a subcutaneous microchamber

The implantable vascularizing microchamber (IVM) by Procyon (Fig 1A) is designed to provide a means for rapid, consistent absorption of insulin without repeated needle (or pen or pump cannula) injections; it measures 1.5 cm² in surface area per side. Its surface is engineered to promote rapid vascularization. Published reports suggested that to be effectively vascularized, subcutaneously implanted devices typically require three to four weeks in mice [45, 46], two to four weeks in rats [47], and two months or less in primates [48]. We therefore conducted the insulin kinetics assays at 28 days after implantation, anticipating mature vascularization by that time. Diluted insulin human

It is made available under a CC-BY 4.0 International license .

was instilled into the IVM at the same dose by body weight as in the SC injection control studies,described above.

217	At 28 days after implantation, 10 of the 12 individual plasma insulin curves peaked just five
218	minutes after injection (Fig 2B), as did the mean value (Fig 2D). The T _{max} for insulin (Table 1) was
219	calculated as 7.50 (SD 4.52, 95% CI 4.626–10.37) min versus 22.7 (SD 14.2) min with conventional
220	SC injection, a statistically significant difference ($p = 0.0020$, Table 1). Not only was uptake of
221	insulin from the microchamber accelerated but the inter-subject variability appeared reduced (Fig
222	2B); this was also attested by the standard deviations of the mean peak (Table 1) and of the early time
223	points of the insulin curve (Fig 2D). Together, the data at day 28 after implantation, indicate that
224	insulin absorption from the IVM is significantly accelerated with improved inter-subject consistency,
225	compared to conventional SC needle injection.

226 Evidence of vascularization revealed by histopathology of retrieved

227 **IVMs**

The peak insulin data presented in the preceding section strongly support the notion that vascularization of the SC tissues surrounding and invading the vascularizing membranes of the microchambers had matured by 28 days and had thereby facilitated the very rapid uptake of insulin. If so, histologic evidence of blood vessels immediately adjacent to the microchambers is likewise expected in the same time frame.

To examine this supposition, IVMs implanted subcutaneously in rats for 7, 21 and 40 days were retrieved and examined histologically. Although the 1.5 cm² microchambers were identical to the ones used for insulin kinetics studies, they had not been injected with insulin to avoid

It is made available under a CC-BY 4.0 International license .

236	confounding effects on morphology that might be induced by the diffusion of human insulin into the
237	surrounding rat subcutaneous tissues. At 7 days after implantation (Fig 3A) a few vessels can be
238	identified but by day 21, subcutaneous vessels in proximity to the vascularizing membranes are both
239	prominent and plentiful (Fig 3B). Images of subcutaneous tissue surrounding the microchambers at
240	40 days (Fig 3C-F) reveal the presence of mature vasculature structures with larger vessels quite
241	close to the inner membranes of the IVMs. There was no histologic evidence of fibrotic overgrowth,
242	even at the latest time point. Thus, the histopathology of explanted IVMs indicates that
243	vascularization begins soon after implantation; the numbers of blood vessels greatly increase by three
244	to about six weeks after implantation, an observation congruent with the increased rapidity of insulin
245	uptake on day 28.
246	
247	Fig 3. Histopathologic images of retrieved microchambers and the surrounding subcutaneous
248	tissues
249	The images of H & E (hematoxylin and eosin)-stained sections, using 20X (A-C) and 40X (D-F)
250	objectives, of IVMs retrieved 7, 21 or 40 days after implantation. The arrows point to vascular
251	structures. For orientation purposes, the image in C is labeled to identify the surrounding (SC) tissue
252	and the <i>insulin delivery chamber</i> . The linear structure (gray) is the inner membrane of the IVM.
253	
-	

254 **Discussion**

Here we report that a small (1.5 cm² surface area per side), specially engineered PTFE,
 vascularizing microchamber (Fig 1) implanted subcutaneously facilitates more rapid uptake of

It is made available under a CC-BY 4.0 International license .

insulin than conventional SC injection. The IVM recruits the growth of blood vessels which establish
a surrounding vasculature, which fully matures by about one month (Fig 3). Regular insulin human
(Humulin R), when instilled into the IVM 28 days after implantation, achieves peak plasma
concentrations significantly faster than an identical dose delivered by conventional SC injection, 7.50
versus 22.7 min (Fig 2, Table 1). Additionally, inter-subject variability was reduced (Fig 2A,B). We
therefore conclude that the subcutaneously implanted microchambers are functionally mature within
weeks, not months.

The subcutaneous space is favored for insulin injection for patient convenience: it is a large space readily accessible for injection and easily examined for problems at the sites of skin penetration. Physiologically, however, it is less than ideal; its vascularity is both sparse and heterogenous. Moreover, repeated injections may generate inflammation and consequent fibrosis, rendering the microenvironment even less conducive to absorption of injected insulin. Finally, utilizing the SC space for insulin delivery currently requires repeated injections, by needle, pen or pump, their frequency depending upon the chosen insulin formulation(s) and the means of injection.

271 The primary clinical scenario for which we envisage the IVM achieving clinical utility for 272 T1DM patients (Fig 1) is a conceptual extension of the experiments described in this report – namely, 273 implantation in diabetic patients to facilitate the very rapid uptake of regular insulin. One might argue 274 that accelerating absorption via an IVM is an unnecessary redundancy now that ultra-rapid acting 275 insulins are available. However, the very rapid peak plasma insulin concentrations achieved with 276 regular insulin via IVM more closely mimic the normal human pancreas and are likely superior to 277 even ultra-rapid acting insulins injected SC [16, 49, 50]. The insulin kinetic curves (Fig 2 B, D) are 278 compatible with an "inject-eat continuum" strategy: this would, first, synchronize the insulin peak 279 with the prandial requirement; and second, avoid the pitfalls of inopportune delays of a meal by

It is made available under a CC-BY 4.0 International license .

simply postponing the injection. As shown in Fig 1, an insulin pump is easily connected to an IVM, ensuring rapid uptake of the pumped insulin; this would allow greater precision in dosing and rapid uptake of prandial boluses. Other challenging clinical scenarios would likewise benefit from rapid uptake of insulin and therefore better glucose control. One example is insulin therapy of diabetics during pregnancy, where precise glucose homeostasis is vital to the well-being, both immediate and long-term, of mother and fetus [51].

286 Another argument sometimes made is that rapid uptake of insulin confers more risk than 287 benefit, for example, by triggering hypoglycemic episodes. However, the clinical safety and efficacy, 288 especially in post-prandial control, of ultra-rapid acting insulins is now supported by many studies 289 [15, 16, 52, 53]. The factitious "too rapid" assertion also deflects the many advances in continuous 290 glucose monitoring (CGM) devices, insulin dosage-predicting algorithms, precision-dosing insulin 291 pumps, open and closed loop systems, and the "artificial pancreas" (AP) [6]. To this point, a recent, 292 comprehensive review of multiple input AP systems [54], identified two persistent challenges: lag 293 times in acquiring blood glucose concentration data, and delays in absorption of insulin from SC 294 depots. Our study is relevant to the latter concern, which echoes an earlier sentiment: for APs (and 295 similar approaches) to achieve their full potential, the "applied insulin should induce ideally an 296 instantaneous effect" [4]. The IVM potentially offers a clinical means of further closing the gap 297 between insulin dose and blood glucose response.

298 Conclusion

Regular insulin human instilled into SC implantable vascularizing microchambers (IVMs)
implanted 28 days previously in diabetic rats attains mean peak plasma insulin concentrations in 7.5
(SD 4.50) min, versus 22.7 (SD 14.2) min following conventional SC injection. Inter-subject

It is made available under a CC-BY 4.0 International license .

- 302 variability was likewise reduced. Histologically, mature vascularization was evident at 21 and 40
- 303 days after implantation, indicating that neovascularization surrounding the IVMs contributed to the
- 304 rapidity of insulin uptake. We suggest that the implantable vascularizing microchambers reported
- 305 herein have clinical potential for the painless, repetitive, reproduceable delivery of regular insulin
- 306 with an absorption rate potentially exceeding that of ultra-rapid acting insulins.

307 Acknowledgements

- 308 The authors wish to acknowledge Chan A. Ion and Jennifer Kitzmann-Miner for their assistance in
- 309 preparing graphic work.

310 **References**

1. Matveyenko AV, Liuwantara D, Gurlo T, Kirakossian D, Dalla Man C, Cobelli C, et al.

312 Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. Diabetes.

313 2012;61(9):2269-79. Epub 20120611. doi: 10.2337/db11-1462. PubMed PMID: 22688333; PubMed
 314 Central PMCID: PMCPMC3425431.

Linsley PS, Greenbaum CJ, Nepom GT. Uncovering Pathways to Personalized Therapies in
Type 1 Diabetes. Diabetes. 2021;70(4):831-41. doi: 10.2337/db20-1185. PubMed PMID: 33741606;
PubMed Central PMCID: PMCPMC7980192.

318 3. Kramer CK, Retnakaran R, Zinman B. Insulin and insulin analogs as antidiabetic therapy: A
perspective from clinical trials. Cell Metab. 2021;33(4):740-7. doi: 10.1016/j.cmet.2021.03.014.
PubMed PMID: 33826916.

Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci
 Technol. 2012;6(4):728-42. Epub 20120701. doi: 10.1177/193229681200600402. PubMed PMID:
 22920797; PubMed Central PMCID: PMCPMC3440142.

Luijf YM, van Bon AC, Hoekstra JB, Devries JH. Premeal injection of rapid-acting insulin
reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care. 2010;33(10):2152-5.
Epub 20100806. doi: 10.2337/dc10-0692. PubMed PMID: 20693354; PubMed Central PMCID:
PMCPMC2945151.

328 6. Domingo-Lopez DA, Lattanzi G, L HJS, Wallace EJ, Wylie R, O'Sullivan J, et al. Medical
329 devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus. Adv
330 Drug Deliv Rev. 2022;185:114280. Epub 20220408. doi: 10.1016/j.addr.2022.114280. PubMed
331 PMID: 35405298.

It is made available under a CC-BY 4.0 International license .

332 7. Becker RH, Frick AD, Burger F, Scholtz H, Potgieter JH. A comparison of the steady-state
333 pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine,
334 and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin

335 Endocrinol Diabetes. 2005;113(5):292-7. doi: 10.1055/s-2005-865637. PubMed PMID: 15926116.

Bode BW. Comparison of pharmacokinetic properties, physicochemical stability, and pump
 compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine. Endocr Pract.
 2011;17(2):271-80. doi: 10.4158/ep10260.Ra. PubMed PMID: 21134878.

Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, et al. Monomeric insulins
obtained by protein engineering and their medical implications. Nature. 1988;333(6174):679-82. doi:
10.1038/333679a0. PubMed PMID: 3287182.

Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22(9):1501-6. doi: 10.2337/diacare.22.9.1501. PubMed PMID: 10480516.

Sheldon B, Russell-Jones D, Wright J. Insulin analogues: an example of applied medical
science. Diabetes Obes Metab. 2009;11(1):5-19. doi: 10.1111/j.1463-1326.2008.01015.x. PubMed
PMID: 19120431.

349 12. Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of
350 diabetes: insulin analogs. Endocr Rev. 2001;22(5):706-17. doi: 10.1210/edrv.22.5.0442. PubMed
351 PMID: 11588149.

13. Kildegaard J, Buckley ST, Nielsen RH, Povlsen GK, Seested T, Ribel U, et al. Elucidating the
Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide. Pharm Res.
2019;36(3):49. Epub 20190211. doi: 10.1007/s11095-019-2578-7. PubMed PMID: 30746556;
PubMed Central PMCID: PMCPMC6373292.

Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and
clinical implications. Diabetes Care. 1990;13(9):923-54. doi: 10.2337/diacare.13.9.923. PubMed
PMID: 2226110.

359 15. Wong EY, Kroon L. Ultra-Rapid-Acting Insulins: How Fast Is Really Needed? Clin Diabetes.
360 2021;39(4):415-23. doi: 10.2337/cd20-0119. PubMed PMID: 34866783; PubMed Central PMCID:
361 PMCPMC8603316.

16. Heise T, Piras de Oliveira C, Juneja R, Ribeiro A, Chigutsa F, Blevins T. What is the value of
faster acting prandial insulin? Focus on ultra rapid lispro. Diabetes Obes Metab. 2022. Epub
20220519. doi: 10.1111/dom.14773. PubMed PMID: 35593434.

365 17. Narayan RJ. Transdermal delivery of insulin via microneedles. J Biomed Nanotechnol.
366 2014;10(9):2244-60. doi: 10.1166/jbn.2014.1976. PubMed PMID: 25992456.

Malone JI, Lowitt S, Grove NP, Shah SC. Comparison of insulin levels after injection by jet
stream and disposable insulin syringe. Diabetes Care. 1986;9(6):637-40. doi:

369 10.2337/diacare.9.6.637. PubMed PMID: 3542456.

19. Pehling GB, Gerich JE. Comparison of plasma insulin profiles after subcutaneous

administration of insulin by jet spray and conventional needle injection in patients with insulin-

dependent diabetes mellitus. Mayo Clin Proc. 1984;59(11):751-4. doi: 10.1016/s0025-

373 6196(12)65585-2. PubMed PMID: 6387316.

It is made available under a CC-BY 4.0 International license .

Dirnena-Fusini I, Åm MK, Fougner AL, Carlsen SM, Christiansen SC. Physiological effects 374 20. 375 of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: A 376 systematic review and meta-analysis. PLoS One. 2021;16(4):e0249611. Epub 20210413. doi: 377 10.1371/journal.pone.0249611. PubMed PMID: 33848314; PubMed Central PMCID: 378 PMCPMC8043377. 379 21. van Dijk PR, Logtenberg SJ, Gans RO, Bilo HJ, Kleefstra N. Intraperitoneal insulin infusion: 380 treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia. Clin Endocrinol (Oxf). 2014;81(4):488-97. Epub 20140728. doi: 10.1111/cen.12546. PubMed PMID: 381 382 25041605. 383 22. Al-Tabakha MM. Future prospect of insulin inhalation for diabetic patients: The case of 384 Afrezza versus Exubera. J Control Release. 2015;215:25-38. Epub 20150726. doi: 385 10.1016/j.jconrel.2015.07.025. PubMed PMID: 26222134. 386 23. Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an 387 ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol. 2012;6(4):773-9. Epub 20120701. doi: 10.1177/193229681200600406. PubMed PMID: 22920801; PubMed Central PMCID: 388 389 PMCPMC3440146. 390 24. Bally L, Thabit H, Hovorka R. Finding the right route for insulin delivery - an overview of 391 implantable pump therapy. Expert Opin Drug Deliv. 2017;14(9):1103-11. Epub 20161207. doi: 392 10.1080/17425247.2017.1267138. PubMed PMID: 27911116; PubMed Central PMCID: 393 PMCPMC5581917. 394 25. Spaan N, Teplova A, Stam G, Spaan J, Lucas C. Systematic review: continuous 395 intraperitoneal insulin infusion with implantable insulin pumps for diabetes mellitus. Acta Diabetol. 396 2014;51(3):339-51. Epub 20140305. doi: 10.1007/s00592-014-0557-3. PubMed PMID: 24595518. 397 26 Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 398 2002;4(5):673-82. doi: 10.1089/152091502320798312. PubMed PMID: 12450450. 399 Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject 27. 400 variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 401 diabetes. Diabetes. 2004;53(6):1614-20. doi: 10.2337/diabetes.53.6.1614. PubMed PMID: 15161770. 402 28. Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M. Reduction in 403 intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-404 administration with recombinant human hyaluronidase in healthy volunteers. Diabetes Technol Ther. 405 2011;13(10):1039-45. Epub 20110629. doi: 10.1089/dia.2011.0115. PubMed PMID: 21714645. 406 29. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 407 2003;26(6):1902-12. doi: 10.2337/diacare.26.6.1902. PubMed PMID: 12766131. 408 30. Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size 409 of the problem. Diabetes Metab Res Rev. 2004;20 Suppl 2:S32-42. doi: 10.1002/dmrr.514. PubMed PMID: 15551297. 410 411 31. Han D, Rahimi E, Aramideh S, Ardekani AM. Transport and Lymphatic Uptake of 412 Biotherapeutics Through Subcutaneous Injection. J Pharm Sci. 2022;111(3):752-68. Epub 20211006. 413 doi: 10.1016/j.xphs.2021.09.045. PubMed PMID: 34624293.

414 32. Hildebrandt P. Subcutaneous absorption of insulin in insulin-dependent diabetic patients.

Influence of species, physico-chemical properties of insulin and physiological factors. Dan Med Bull.
1991;38(4):337-46. PubMed PMID: 1914533.

417 33. Hildebrandt P. Skinfold thickness, local subcutaneous blood flow and insulin absorption in
418 diabetic patients. Acta Physiol Scand Suppl. 1991;603:41-5. PubMed PMID: 1789128.

419 34. Hildebrandt PR, Vaag AA. Local skin-fold thickness as a clinical predictor of depot size

420 during basal rate infusion of insulin. Diabetes Care. 1993;16(1):1-3. doi: 10.2337/diacare.16.1.1.
421 PubMed PMID: 8422761.

Gradel AKJ, Porsgaard T, Brockhoff PB, Seested T, Lykkesfeldt J, Refsgaard HHF. Delayed
insulin absorption correlates with alterations in subcutaneous depot kinetics in rats with diet-induced
obesity. Obes Sci Pract. 2019;5(3):281-8. Epub 20190318. doi: 10.1002/osp4.326. PubMed PMID:
31275602; PubMed Central PMCID: PMCPMC6587326.

426 36. Hajheydari Z, Kashi Z, Akha O, Akbarzadeh S. Frequency of lipodystrophy induced by
427 recombinant human insulin. Eur Rev Med Pharmacol Sci. 2011;15(10):1196-201. PubMed PMID:
428 22165682.

37. Radermecker RP, Piérard GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of
continuous insulin infusion and new insulin analogs. Am J Clin Dermatol. 2007;8(1):21-8. doi:
10.2165/00128071-200708010-00003. PubMed PMID: 17298103.

432 38. Gradel AKJ, Porsgaard T, Lykkesfeldt J, Seested T, Gram-Nielsen S, Kristensen NR, et al.
433 Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability. J
434 Diabetes Res. 2018;2018:1205121. Epub 20180704. doi: 10.1155/2018/1205121. PubMed PMID:
435 30116732; PubMed Central PMCID: PMCPMC6079517.

436 39. Kanapka LG, Lum JW, Beck RW. Insulin Pump Infusion Set Failures Associated with
437 Prolonged Hyperglycemia: Frequency and Relationship to Age and Type of Infusion Set During
438 22,741 Infusion Set Wears. Diabetes Technol Ther. 2022;24(6):396-402. Epub 20220223. doi:
439 10.1089/dia.2021.0548. PubMed PMID: 35104166.

40. García-Jaramillo M, Calm R, Bondia J, Vehí J. Prediction of postprandial blood glucose
under uncertainty and intra-patient variability in type 1 diabetes: a comparative study of three interval
models. Comput Methods Programs Biomed. 2012;108(1):224-33. Epub 20120605. doi:
10.1016/j.cmpb.2012.04.003. PubMed PMID: 22677264.

444 41. Zheng H, Nathan DM, Schoenfeld DA. Using a multi-level B-spline model to analyze and
445 compare patient glucose profiles based on continuous monitoring data. Diabetes Technol Ther.
446 2011;13(6):675-82. Epub 20110413. doi: 10.1089/dia.2010.0199. PubMed PMID: 21488799;
447 PubMed Central PMCID: PMCPMC3101946.

448 42. Brauker JH, Carr-Brendel VE, Martinson LA, Crudele J, Johnston WD, Johnson RC.
449 Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed
450 Mater Res. 1995;29(12):1517-24. doi: 10.1002/jbm.820291208. PubMed PMID: 8600142.

451 43. Nordquist L, Sjöquist M. Improvement of insulin response in the streptozotocin model of

452 insulin-dependent diabetes mellitus. Insulin response with and without a long-acting insulin

453 treatment. Animal. 2009;3(5):685-9. doi: 10.1017/s175173110800387x. PubMed PMID: 22444446.

It is made available under a CC-BY 4.0 International license .

454 44. Friedman M. The Use of Ranks to Avoid the Assumption of Normality Implicit in the 455 Analysis of Variance. Journal of the American Statistical Association. 1937;32(200):675-701. doi: 456 10.1080/01621459.1937.10503522. 457 45. Hussey AJ, Winardi M, Han XL, Thomas GP, Penington AJ, Morrison WA, et al. Seeding of 458 pancreatic islets into prevascularized tissue engineering chambers. Tissue Eng Part A. 459 2009;15(12):3823-33. doi: 10.1089/ten.TEA.2008.0682. PubMed PMID: 19558221. 460 46. Pepper AR, Pawlick R, Gala-Lopez B, MacGillivary A, Mazzuca DM, White DJ, et al. 461 Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a 462 Subcutaneous Cell Pouch Device. Transplantation. 2015;99(11):2294-300. doi: 463 10.1097/tp.000000000000864. PubMed PMID: 26308506; PubMed Central PMCID: 464 PMCPMC4623852. 465 47. Rafael E, Wernerson A, Arner P, Tibell A. In vivo studies on insulin permeability of an 466 immunoisolation device intended for islet transplantation using the microdialysis technique. Eur Surg Res. 1999:31(3):249-58. doi: 10.1159/000008700. PubMed PMID: 10352353. 467 468 48. Sasikala M, Rao GV, Vijayalakshmi V, Pradeep R, Pothani S, Kumar PP, et al. Long-term 469 functions of encapsulated islets grafted in nonhuman primates without immunosuppression. 470 Transplantation. 2013;96(7):624-32. doi: 10.1097/TP.0b013e31829e26cf. PubMed PMID: 23883970. 471 49. Bolli GB, Porcellati F, Lucidi P, Fanelli CG, Owens DR. One-hundred year evolution of 472 prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs. Metabolism. 2022;126:154935. Epub 20211108. doi: 10.1016/j.metabol.2021.154935. PubMed PMID: 34762931. 473 474 50. Owens DR, Bolli GB. The continuing quest for better subcutaneously administered prandial 475 insulins: a review of recent developments and potential clinical implications. Diabetes Obes Metab. 2020;22(5):743-54. Epub 20200203. doi: 10.1111/dom.13963. PubMed PMID: 31930670; PubMed 476 477 Central PMCID: PMCPMC7187182. 478 51. Amigó J, Corcoy R. Type 1 diabetes and pregnancy: An update on glucose monitoring and 479 insulin treatment. Endocrinol Diabetes Nutr (Engl Ed). 2022. Epub 20220701. doi: 480 10.1016/j.endien.2022.06.008. PubMed PMID: 35787359. 481 52. Avgerinos I, Papanastasiou G, Karagiannis T, Michailidis T, Liakos A, Mainou M, et al. Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. Diabetes 482 483 Obes Metab. 2021;23(10):2395-401. Epub 20210622. doi: 10.1111/dom.14461. PubMed PMID: 484 34105242. 485 53. De Block CEM, Van Cauwenberghe J, Bochanen N, Dirinck E. Rapid-acting insulin 486 analogues: Theory and best clinical practice in type 1 and type 2 diabetes. Diabetes Obes Metab. 487 2022. Epub 20220411. doi: 10.1111/dom.14713. PubMed PMID: 35403348. 488 54. Hettiarachchi C, Daskalaki E, Desborough J, Nolan CJ, O'Neal D, Suominen H. Integrating 489 Multiple Inputs Into an Artificial Pancreas System: Narrative Literature Review. JMIR Diabetes. 490 2022;7(1):e28861. Epub 20220224. doi: 10.2196/28861. PubMed PMID: 35200143; PubMed Central 491 PMCID: PMCPMC8914747.



Figure 1



Figure 2



Figure 3